Harm Reduction Therapeutics (HRT), a non-profit pharmaceutical company, has shipped the first order of RiVive, an over-the-counter naloxone nasal spray to prevent opioid overdose deaths. The FDA-approved nasal spray provides a single 3 mg administration for the emergency treatment of opioid overdose without a prescription. RiVive will be distributed to community harm reduction groups that are working to combat opioid overdoses, and HRT is committed to its non-profit model and aims to make RiVive available across the United States free of charge or at a low cost.
HRT emphasizes that no entity or individual, including its unpaid volunteer board of directors and staff, will profit from RiVive sales. The product will be available at cost or less, with a selling price of $36 per twin pack, covering production, packaging, testing, and transportation costs. Additionally, HRT actively seeks additional funding partners to support operations, reduce selling prices, and increase the availability of free-of-charge doses, highlighting the importance of charitable contributions in saving lives amid the opioid crisis.
